FundedIQ
Health Care

Resistell AG: Funding, Investors & Team (Sep 2026)

Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.

resistell.com LinkedIn Basel, Switzerland 11-50 employees
Medical Device
Total raised
$9.2M
Rounds
1
Latest
Series B
Dec 2022

Resistell AG has raised $9.2M across 1 funding round on record, the most recent a Series B of $9.2M announced in Dec 2022.

That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.

Resistell AG Company Profile and Key Stats

Total funding raised
$9.2M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series B
$9.2M in Dec 2022
Employees
11-50
reported band
Headquarters
Basel, Switzerland

Latest funding round on record: Dec 2022.

Resistell AG Funding Rounds

Date
Round
Amount
Series B
$9.2M

Resistell AG Founders and Leadership Team

Name
Role
Contact
Danuta Cichocka
CEO
Locked

Contact details for the Resistell AG team: 1 of 1 has an email address on file.

Start 14-day free trial →

Resistell AG Funding Compared to Other Health Care Startups

Segment
Companies
Median round
3,653
$4.7M
879
$3.8M
4,289
$30M

Resistell AG's latest round of $9.2M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Resistell AG in Health Care and Basel

Companies Similar to Resistell AG

MoleSense is to provide a wearable skin sensor to help monitor high-risk pregnancies.

Undisclosed round $110k

CeQur Simplicity helps people with diabetes by developing drug-delivery devices. They develop bolus insulin…

Series E $100M

Calmea develops advanced contactless sensing systems that invisibly track sleep and automatically modify…

Undisclosed round $190k

NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for…

Series B $33.6M

UNBOOUND is a medtech company and university spin-off (The Rockefeller University and University of Geneva)…

Undisclosed round $130k

Christina Vallgren and Marcus Palm, two physicists from CERN, co-founded Terapet along with Professor Raymond…

Undisclosed round $2.6M
Seed

Axmed is a company that specializes in serving low and middle-income countries (LMICs), with the goal of…

Undisclosed round $6.0M

Babylat is an enricher device is the first automated, small-scale tabletop device for the protein enrichment…

Undisclosed round $1.0M

Altiscreen is creating and producing cutting-edge, portable drug-of-abuse detection systems. With the use of…

Undisclosed round $150k

Vivent provides growers, breeders and agrochem companies with actionable information direct from plants…

Undisclosed round $8.7M

Multiwave develops breakthrough Magnetic Resonance Imaging and Positron Emission Tomography devices. Founded…

Undisclosed round $4.5M

Resistell AG Funding FAQs

What does Resistell AG do?

Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.

How much funding has Resistell AG raised?

Resistell AG has raised $9.2M across 1 round on record. The most recent is a Series B of $9.2M announced in Dec 2022.

When did Resistell AG last raise funding?

Resistell AG's most recent funding round on record is a Series B of $9.2M, announced in Dec 2022.

Who is the CEO of Resistell AG?

Danuta Cichocka is listed as CEO at Resistell AG.

Where is Resistell AG headquartered?

Resistell AG is based in Basel, Basel-Stadt, Switzerland.

How many employees does Resistell AG have?

Resistell AG is in the 11-50 employee band.

How does Resistell AG's funding compare to other Health Care startups?

Resistell AG's latest round of $9.2M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.

About FundedIQ's Resistell AG Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Resistell AG is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.